



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Mr O Schofield
UNIVERSITY COLLEGE LONDON
CANCER RESEARCH UK AND UCL CANCER TRIALS CENTRE, 90 TOTTENHAM COURT ROAD, LONDON,
W1T 4TJ, UNITED KINGDOM

10/06/2020

Dear Mr O Schofield,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 20363/0386/001-0007
Eudract Number:	2017-002544-32
Product:	Opdivo
Protocol number:	UCL/15/0515
Substantial Amendment Code Number:	Code Number: Amendment 6 Version: Protocol v4.0 Date: 2020/05/28

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 28/05/2020.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**